Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

Leukemia. 2022 Mar;36(3):885-888. doi: 10.1038/s41375-021-01431-x. Epub 2021 Nov 3.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Oligopeptides / therapeutic use*
  • Progression-Free Survival

Substances

  • Antibodies, Monoclonal, Humanized
  • Oligopeptides
  • carfilzomib
  • Dexamethasone
  • Lenalidomide
  • isatuximab